Management of coccidioidomycosis in patients receiving biologic response modifiers or disease‐modifying antirheumatic drugs
Authors:
- Sara TaroumianSTSara Taroumian
- Susan L. KnowlesSKSusan L. Knowles
- Jeffrey R. LisseJLJeffrey R. Lisse
- James YanesJYJames Yanes
- Neil M. AmpelNANeil M. Ampel
- John N. GalgianiJGJohn N. Galgiani
- Susan E. HooverSHSusan E. Hoover
Open Access
- 28 June 2012
- journal article
- coccidioidomycosis
- Published by Wiley in Arthritis Care & Research
- Vol. 64 (12) , 1903-1909
Abstract
Objective: Coccidioidomycosis (valley fever) is an endemic fungal infection of the American Southwest, an area with a large population of patients with rheumatic diseases. There are currently no guidelines for management of patients who develop coccidioidomycosis while under treatment with biologic response modifiers (BRMs) or disease‐modifying antirheumatic drugs (DMARDs). We conducted a retrospective study of how both concurrent diseases were managed and the patient outcomes at 2 centers in Tucson, Arizona.Methods: A retrospective chart review identified patients who developed coccidioidomycosis during treatment with DMARDs or BRMs. Patients were seen at least once in a university‐affiliated or Veterans Affairs outpatient rheumatology clinic in Tucson, Arizona, between 2007 and 2009.Results: Forty‐four patients were identified. Rheumatologic treatment included a BRM alone (n = 11), a DMARD alone (n = 8), or combination therapy (n = 25). Manifestations of coccidioidomycosis included pulmonary infection (n = 29), disseminated disease (n = 9), and asymptomatic positive coccidioidal serologies (n = 6). After the diagnosis of coccidioidomycosis, 26 patients had BRMs and DMARDs stopped, 8 patients had BRMs stopped but DMARD therapy continued, and 10 patients had no change in their immunosuppressive therapy. Forty‐one patients had antifungal therapy initiated for 1 month or longer. Followup data were available for 38 patients. BRM and/or DMARD therapy was continued or resumed in 33 patients, only 16 of whom continued concurrent antifungal therapy. None of the patients have had subsequent dissemination or complications of coccidioidomycosis.Conclusion: Re‐treating rheumatic disease patients with a BRM and/or a DMARD after coccidioidomycosis appears to be safe in some patients. We propose a management strategy based on coccidioidomycosis disease activity.Keywords
This publication has 15 references indexed in Scilit:
- The Public Health Impact of Coccidioidomycosis in Arizona and CaliforniaInternational Journal of Environmental Research and Public Health, 2011
- Coccidioidal Pneumonia, Phoenix, Arizona, USA, 2000–2004Emerging Infectious Diseases, 2009
- Coccidioidomycosis in Rheumatology PatientsAnnals of the New York Academy of Sciences, 2007
- Coccidioidomycosis as a Common Cause of Community-acquired PneumoniaEmerging Infectious Diseases, 2006
- Coccidioidomycosis—A Fungal Disease of the AmericasPLOS Medicine, 2005
- Serious Infections Associated with Anticytokine Therapies in the Rheumatic DiseasesJournal of Intensive Care Medicine, 2004
- Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonistsArthritis & Rheumatism, 2004
- Coccidioidomycosis in Solid Organ TransplantationClinical Infectious Diseases, 2001
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Serology of coccidioidomycosisClinical Microbiology Reviews, 1990